Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Armin Rashidi

Showing results (161-170 of 176) with videos related to

Pageof 18
Sort By:
Transplantation and Cellular Therapy|June 6, 2023
Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host DiseaseShernan G Holtan, Andrea Hoeschen, Qing Cao, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 15, 2018
Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aidKhalid Amin, Usman Yaqoob, Brittney Schultz, et al.
Bone Marrow Transplantation|January 9, 2021
Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplantGrigori Okoev, Daniel J Weisdorf, John E Wagner, et al.
JCI Insight|December 8, 2017
Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus controlAnnelise Y Mah, Armin Rashidi, Molly P Keppel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 5, 2018
Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-UpErica Dahl Warlick, Todd E DeFor, Nelli Bejanyan, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in GVHD Risk Without Increased Relapse Risk Compared to Historical Cyclosporine/MethotrexateNajla El Jurdi, Alex Hoover, Daniel O'Leary, et al.
Transplantation and Cellular Therapy|June 13, 2023
Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate MofetilNajla El Jurdi, Alex Hoover, Daniel O'Leary, et al.
American Journal of Hematology|October 7, 2016
Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemiaAshley Rosko, Hai-Lin Wang, Marcos de Lima, et al.
Blood Cancer Journal|May 19, 2021
High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood groupNajla El Jurdi, Heba Elhusseini, Joan Beckman, et al.
Cancer|January 25, 2017
Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysisFotios V Michelis, Vikas Gupta, Mei-Jie Zhang, et al.
Pageof 18

Showing results (161-170 of 176) with videos related to

Sort By:
Pageof 18
Transplantation and Cellular Therapy|June 6, 2023
Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host DiseaseShernan G Holtan, Andrea Hoeschen, Qing Cao, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 15, 2018
Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aidKhalid Amin, Usman Yaqoob, Brittney Schultz, et al.
Bone Marrow Transplantation|January 9, 2021
Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplantGrigori Okoev, Daniel J Weisdorf, John E Wagner, et al.
JCI Insight|December 8, 2017
Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus controlAnnelise Y Mah, Armin Rashidi, Molly P Keppel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 5, 2018
Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-UpErica Dahl Warlick, Todd E DeFor, Nelli Bejanyan, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in GVHD Risk Without Increased Relapse Risk Compared to Historical Cyclosporine/MethotrexateNajla El Jurdi, Alex Hoover, Daniel O'Leary, et al.
Transplantation and Cellular Therapy|June 13, 2023
Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate MofetilNajla El Jurdi, Alex Hoover, Daniel O'Leary, et al.
American Journal of Hematology|October 7, 2016
Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemiaAshley Rosko, Hai-Lin Wang, Marcos de Lima, et al.
Blood Cancer Journal|May 19, 2021
High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood groupNajla El Jurdi, Heba Elhusseini, Joan Beckman, et al.
Cancer|January 25, 2017
Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysisFotios V Michelis, Vikas Gupta, Mei-Jie Zhang, et al.
Pageof 18